Rheumatology

From 1999 to 2015, permanent disability claims for patients with rheumatoid arthritis (RA) spiked during periods of economic recessions, suggesting that the COVID-19 pandemic may create a similar effect in the near future.

The novel systemic-immune inflammation index (SII) can be used to predict the onset of psoriasis.

Multimorbidity affects 1 in 4 US adults and leads to increased health care use and lower quality of life.

The results from an analysis of patients from 12 rheumatology centers treated with secukinumab for psoriatic arthritis were in line with earlier pivotal trials, the researchers said.

Abatacept was shown to have a 9% increase in likelihood of achieving remission compared with conventional therapy for rheumatoid arthritis (RA), which the researchers contribute to the treatment’s lower discontinuation rates.

After 4 weeks of a standard treatment regimen, patients demonstrated a 75% reduction in the Psoriasis Area and Severity Index score (PASI).

A recent study took a look at the use of biologics for generalized pustular psoriasis, a rare, potentially life-threatening inflammatory disorder.

An apparent first case of psoriatic arthritis triggered by coronavirus disease 2019 (COVID-19) was reported in a genetically predisposed patient.

Secukinumab rarely leads to latent tuberculosis infection as a reported adverse event and is supported for use in treating chronic systemic inflammatory conditions.

The American College of Rheumatology (ACR) announced a number of policy priorities that it is encouraging the new Congress and administration to focus on during the year.

The study sought to understand how psoriasis treatments perform in real-world settings.

CMS finalized a rule on electronic data entry that will streamline the prior authorization process and improve data transparency for providers, payers, and patients.

Study findings, published in Frontiers in Medicine, underscore the importance of metabolic profiling for discovering candidate screening biomarkers for interstitial lung disease (ILD) in rheumatoid arthritis.

In an unexpected finding, patients with psoriasis showed similar hand impairment to patients with psoriatic arthritis and rheumatoid arthritis.

A Greek study examined the prevalence of comorbidities in patients with rheumatoid arthritis (RA), diabetes, and psoriatic arthritis (PsA).

Both secukinumab 300 mg and secukinumab 150 mg significantly improved signs and symptoms of axial disease in patients with psoriatic arthritis (PsA) who had inadequate response to non- steroidal anti-inflammatory drugs.

The study showed that that patients with higher disease activity had significantly lower levels of physical activity.

Integrated health system specialty pharmacies provide specialized services to patients, resulting in high rates of adherence to and financial assistance with specialty disease-modifying antirheumatic drugs.

In the real world, the persistence rate with secukinumab to treat psoriatic arthritis was higher than with ustekinumab.

Using machine learning methods researchers were able to extract records of patients with rheumatoid arthritis (RA) from electronic health record data with high precision, enabling research on very large populations with this condition for limited costs.

At its annual meeting, the American College of Rheumatology previewed updates to guidelines for the management of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).

Although half of US rheumatologists have patients for which nonmedical switching has been suggested, only 35% were likely to switch patients with rheumatoid arthritis doing well on a reference product to a biosimilar.

Improvements in completed visits while using telemedicine to conduct rheumatology visits during the coronavirus disease 2019 pandemic may present an option for continued telemedicine use for follow-up care.

The study also found that Black patients with rheumatoid arthritis (RA) are more likely to be prescribed glucocorticoids, which come with a risk of serious long-term adverse effects.

New results from the phase 3 ULTIMATE trial show Novartis’ Cosentyx (secukinumab) demonstrated significant treatment response on synovitis in patients with active psoriatic arthritis (PsA) compared with placebo.

Despite concerns about treatment with immunosuppressive agents, coronavirus disease 2019 (COVID-19) infection remains low in patients with rheumatic diseases, according to 2 abstracts presented at the annual meeting of the American College of Rheumatology.

The American College of Rheumatology (ACR) has joined forces with other provider groups to oppose a plan proposed by UnitedHealthcare that would increase patients’ out-of-pocket costs.

Patients with psoriatic arthritis with enthesitis are more likely to have severe disease than patients without enthesitis, and they and their physicians are less likely to be satisfied with their treatments.

In the first wave of the coronavirus disease 2019 pandemic, patients with axial spondyloarthritis, rheumatoid arthritis, and psoriatic arthritis didn’t have an increase in disease activity despite an interruption in in-person interactions.

Despite the benefits of switching to a different mode of action in the second line, almost half of patients with rheumatoid arthritis were cycled to a second tumor necrosis factor inhibitor.